Decision Diagnostics Corp. (OTC Pink: DECN) gains 40% after Launching Its Genultimate 4Pets and Avantage Meter

EmergingGrowth.com - Decision Diagnostics Corp. (OTC Pink: DECN) gains 40% after Launching Its Genultimate 4Pets and Avantage Meter
EmergingGrowth.com - Decision Diagnostics Corp. (OTC Pink: DECN) gains 40% after Launching Its Genultimate 4Pets and Avantage Meter

Miami, FL – March 14, 2019 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on Decision Diagnostics Corp. (OTC Pink: DECN).

Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN’s products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. 

Average daily volume for DECN is 350 thousand shares. Today’s news has caused the volume to increase to over 4.3 million shares in the morning hours of trading.

Decision Diagnostics Corp. Press Release:

LOS ANGELES, CA / ACCESSWIRE / March 14, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 17 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips.

Decision Diagnostics is pleased to announce and communicate that the company, through its PharmaTech Solutions, Inc. subsidiary has, as discussed previously, commercially launched its GenUltimate! 4Pets glucose test strips and the Avantage meter for at-home testing of dogs, cats and horses where elevated glucose levels are of concern to the pet owner. This market has grown by leaps and bounds in the past 24 months. The company is pre-selling GenUltimate! 4Pets on Amazon, Walmart and other large on-line retailers, but also has also pre-sold product to a large pet products manufacturer and distributor who counts PetSmart and PetCo as luminary clients. Deliveries are forecast to commence in 3Q 2019.

Keith Berman, CEO of DECN commented, “GenUltimate! 4Pets is our latest product entry for the pet testing market. We have launched GenUltimate! 4Pets with a unique merchandising program that will rebate to the buyer the full cost of our Avantage! meter when the buyer provides his/her older Zoetis Alpha Trak meter in trade. We will continue to market and sell our successful PetSure! test strips to Zoetis Alpha Trak users. Our goal is to get a lock on this fast growing testing industry.”

The company’s current portfolio of test strips includes its market established GenUltimate!, plus its GenChoice!, GenSure!, and GenUltimate! TBG test strips, its Avantage! and Precise! Glucometers, and its PetSure! and GenUltimate! 4Pets testing products for dogs, cats and horses. The company’s GenChoice! test strips are part of a current 510K prosecution process with the U.S. FDA. The company’s GenUltimate! TBG test strips and meter are entering patient clinical trials.

Mr. Berman continued, “We are putting all available resources and energy into our quickly growing product lines. The next update we provide will include a detailed discussion of our GenUltimate! TBG panacea product that will enter clinical trials and third party testing at the outset of 2Q 2019.”

ABOUT DECISION DIAGNOSTICS CORP

Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN’s products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $12 billion at-home testing market.

Forward-Looking Statements

This release contains the company’s forward-looking statements which are based on management’s current expectations and assumptions as of March 13, 2019, regarding the company’s business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

Contact Information: 

Decision Diagnostics Corp.
Keith Berman (805) 446-2973

info@decisiondiagnostics.com
www.genultimate.com
www.petsureteststrips.com
www.pharmatechdirect.com

SOURCE: Decision Diagnostics Corp.


About EmergingGrowth.com

EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies.  Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization.  We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth.  Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community.  Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information may include certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  EmergingGrowth.com, or its associates may have a position either long or short in any company mentioned herein. Please read our full disclosure, which can be found here, http://emerginggrowth.com/disclosure/. Please consult an investment professional before investing in anything viewed within this article or any other portion of EmergingGrowth.com. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.

Add a Comment to this Post

comments